{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:21:31Z","timestamp":1782836491518,"version":"3.54.5"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perit Dial Int"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Patients with dialysis have a high risk of osteoporosis and fractures. However, the optimal treatment strategies for osteoporosis in dialysis patients remain unclear due to the complexity of chronic kidney disease (CKD)\u2013mineral and bone disorder. This case report describes severe symptomatic hypocalcemia and prolonged heart failure following denosumab treatment in a peritoneal dialysis (PD) patient with secondary hyperparathyroidism and osteoporosis. A 70-year-old woman on PD for dialysis caused by diabetic nephropathy was diagnosed with osteoporosis (T score \u22122.5) during a routine checkup. Denosumab, a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor, was administered following an increase in active vitamin D analog levels. One month later, she developed tetany, making it difficult to perform PD. Two days later, she was hospitalized with breathing difficulties and diagnosed with severe hypocalcemia and heart failure. Heart failure was attributed to mild fluid overload and reduced cardiac contractility due to hypocalcemia. Treatment with calcium supplementation and hemodialysis alleviated her symptoms and improved cardiac function. Denosumab is a promising option for osteoporosis in dialysis patients, but it poses a significant risk of severe hypocalcemia, especially in those with secondary hyperparathyroidism. Reports of such complications in PD patients are rare. Clinicians should carefully monitor serum calcium levels, implement preventive strategies, and promptly address complications when using denosumab in this population. In this case, cardiac function remained impaired for at least 6 months, suggesting prolonged heart failure following denosumab-associated hypocalcemia.<\/jats:p>","DOI":"10.1177\/08968608251361322","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:13:56Z","timestamp":1753258436000},"page":"396-399","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe symptomatic hypocalcemia and prolonged heart failure after treatment of osteoporosis with denosumab in a peritoneal dialysis patient: A case report"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6769-424X","authenticated-orcid":false,"given":"Keisuke","family":"Yoshida","sequence":"first","affiliation":[{"name":"St Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-8938","authenticated-orcid":false,"given":"Shigeki","family":"Kojima","sequence":"additional","affiliation":[{"name":"St Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-0483","authenticated-orcid":false,"given":"Tsutomu","family":"Sakurada","sequence":"additional","affiliation":[{"name":"St Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.03.012"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.28239"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61459-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.06.019"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/08968608231181264"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0896860819880095"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000213"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl245"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa359"},{"key":"e_1_3_3_12_2","article-title":"Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis","author":"Masuda S","unstructured":"Masuda S, Fukasawa T, Matsuda S, et al. Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis. Ann Intern Med 2025; 178(2): 167\u2013176.","journal-title":"Ann Intern Med"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00821.2005"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-013-9371-1"},{"key":"e_1_3_3_15_2","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease\u202f: a target trial emulation","author":"Bird ST","unstructured":"Bird ST, Gelperin K, Smith ER, et al. The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease\u202f: a target trial emulation. Ann Intern Med 2024; 178(1): 29\u201338.","journal-title":"Ann Intern Med"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03325272"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103572"},{"key":"e_1_3_3_18_2","first-page":"201","article-title":"Hypocalcemic cardiomyopathy due to untreated hypoparathyroidism","volume":"59","author":"Altunba\u015f H","year":"2003","unstructured":"Altunba\u015f H, Balci MK, Yazicio\u01e7lu G, et al. Hypocalcemic cardiomyopathy due to untreated hypoparathyroidism. Horm Res 2003; 59: 201\u2013204.","journal-title":"Horm Res"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1154"}],"container-title":["Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08968608251361322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08968608251361322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08968608251361322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:48:21Z","timestamp":1781092101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08968608251361322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/08968608251361322"],"URL":"https:\/\/doi.org\/10.1177\/08968608251361322","relation":{},"ISSN":["0896-8608","1718-4304"],"issn-type":[{"value":"0896-8608","type":"print"},{"value":"1718-4304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}